Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-09-15

Clinical Trial Update: Study of Treatment Used for Migraine Headaches (MK-0974-076)

View source ↗

Summary

A Merck-sponsored trial evaluating telcagepant (MK-0974) for migraine was terminated. Results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Telcagepant (telcagepant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Migraine | Status: TERMINATED | Results posted: 2014-09-15